The above part of the symposium announcement from May 2018 (the subject of this thread) refers to Dr Pedro Nieto, who had also contributed to the 2016 Midkine Symposium. See here: http://www.cellmid.com.au/content_common/pg-pedro-nieto-mk-symposium-2016.seo or click on the thumbnail:
It seems to me that research into a better understanding of Mdikine biology is being intensified by Dr Nieto at University of Seville. They seem to be hiring a scientist for a project at their research centre cicCartuja, in particular the Glycosystems Laboratory.
Project Description:
Download link: https://eshorizonte2020.es/expressions/pdf/52649
"This interaction is at the origin of their function but also is at pathological processes as tumorigenesis, angiogenesis. We have already detected and performed a preliminary analysis of the interactions between MK or PTN and CS derivatives. From this project a progress into the comprehension of the molecular basis of their activity is expected."
What exactly that means is beyond my knowledge but research in this area is obviously being pursued further.
- Forums
- ASX - By Stock
- Ann: Midkine Symposium Munich
[ATTACH] The above part of the symposium announcement from May...
-
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online